All In Biotech

Drug Trial Radar · NCT05013229

A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Insulin Glargine Taken Daily With Insulin Aspart (COMBINE 3)

A 52 Week Study Comparing the Efficacy and Safety of Once Weekly IcoSema and Daily Insulin Glargine 100 Units/mL Combined With Insulin Aspart, Both Treatment Arms With or Without Oral Anti Diabetic Drugs, in Participants With Type 2 Diabetes Inadequately Controlled With Daily Basal Insulin. COMBINE 3

Last checked: Nov 20, 2026Latest source record: Dec 2, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 679 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

679

Actual

Start

Nov 30, 2021

Primary completion

Nov 14, 2023

Study completion Nov 14, 2023

Sponsor

Lead sponsor
Novo Nordisk A/SNovo Nordisk (NVO)
Sponsor type
Industry
First posted
Aug 19, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will compare the new medicine IcoSema, which is a combination of insulin icodec and semaglutide, taken once a week, to insulin glargine taken daily with insulin aspart in people with type 2 diabetes.The study will look at how well IcoSema controls blood sugar level in people with type 2 diabetes compared to insulin glargine taken with insulin aspart. Participants will either get IcoSema or insulin glargine taken with insulin aspart. Which treatment participants get is decided by chance. IcoSema is a new medicine that doctors cannot prescribe. Doctors can already prescribe insulin glargine and insulin aspart in many countries. Participants will get IcoSema or insulin glargine together with insulin aspart. Participants must inject IcoSema once a week or inject insulin glargine once daily and insulin aspart 2-4 times a day. Participants will inject the medicines with a pen, which has a small needle, in a skin fold in the thigh, upper arm, or stomach. The study will last for about 1 year and 1 month. Participants will be asked to wear a sensor that measures participants blood sugar level all the time during an 8 week period at the beginning of the study and a 4 week period at the end of the study. Women cannot take part if pregnant, breast-feeding or plan to get pregnant during the study period.

Conditions

  • Diabetes Mellitus, Type 2

Interventions

  • IcoSemaDrug

    Participants will receive a once weekly subcutanous (s.c.) injection of IcoSema, on the same day every week for 52 weeks.

  • Insulin glargineDrug

    Participants will receive a once daily subcutaneous (s.c.) injection of insulin glargine combined with Insulin aspart 2-4 times a day during mealtimes for 52 weeks.

  • insulin aspartDrug

    Participants will receive a once daily subcutaneous (s.c.) injection of insulin glargine combined with Insulin aspart 2-4 times a day during mealtimes for 52 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in HbA1cTime frame: From baseline week 0 (V2) to week 52 (V54)

Locations

182 sites in 14 countries. Site status is shown where the registry gives one.

  • Lakeview Clinical Research, LLC

    Guntersville, Alabama

  • Valley Research

    Fresno, California

  • Scripps Wht Diab Inst La Jolla

    La Jolla, California

  • Torrance Clin Res Inst, Inc.

    Lomita, California

  • Downtown LA Res Ctr. Inc.

    Los Angeles, California

  • San Diego Family Care

    San Diego, California

  • NorCal Endocrinology and Internal Medicine

    San Ramon, California

  • Creekside Endocrine Associates

    Denver, Colorado

  • Clinical Res Of W Florida Inc

    Clearwater, Florida

  • Northeast Research Institute

    Fleming Island, Florida

  • Sweet Hope Research Specialty

    Hialeah, Florida

  • E Coast Inst for Rsrch LLC_Jacksonville

    Jacksonville, Florida

  • Northeast Res Inst. Inc.

    Jacksonville, Florida

  • East Coast Institute for Research, LLC

    Jacksonville, Florida

  • South Broward Research LLC

    Miramar, Florida

  • Adult Medicine of Lake County, Inc.

    Mt. Dora, Florida

  • Renstar Medical Research

    Ocala, Florida

  • Florida Inst For Clin Res

    Orlando, Florida

  • Metabolic Research Institute Inc

    West Palm Beach, Florida

  • Physicians Research Assoc. LLC

    Lawrenceville, Georgia

  • Endo Res Solutions Inc

    Roswell, Georgia

  • East West Med Res Inst

    Honolulu, Hawaii

  • Saltzer Medical Group Research

    Nampa, Idaho

  • Endeavor Health

    Skokie, Illinois

  • Iowa Diab & Endo Res Center

    West Des Moines, Iowa

  • Cotton-O'Neil Diab & Endo Ctr

    Topeka, Kansas

  • The Research Group of Lexington LLC

    Lexington, Kentucky

  • New Orleans Center for Clinical Research

    New Orleans, Louisiana

  • MedStar Hlth Res Institute

    Hyattsville, Maryland

  • ActivMed Practice & Research LLC

    Methuen, Massachusetts

  • Northern Pines Hlth Ctr, PC

    Buckley, Michigan

  • StudyMetrix Research LLC

    City of Saint Peters, Missouri

  • Univ of Nebraska Medical CTR

    Omaha, Nebraska

  • Palm Research Center Inc-Vegas

    Las Vegas, Nevada

  • Southern NH Diabetes and Endocrinology

    Nashua, New Hampshire

  • John J Shelmet, MD

    Lawrenceville, New Jersey

  • Mid Hudson Med Res-New Windsor

    New Windsor, New York

  • DiGiovanna Institute for Medical Education & Research

    North Massapequa, New York

  • Southgate Medical Group, LLP

    West Seneca, New York

  • Physicians East Endocrinology

    Greenville, North Carolina

Showing 40 of 182 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.